OMEROS CORP. news, videos and press releases - Page 4
For more news please use our advanced search feature.
OMEROS CORP. - More news...
OMEROS CORP. - More news...
- Omeros’ OMS906 Data Presented at Complement-based Drug Development Summit
- Omeros Schedules Webcast to Present Final Efficacy Results from Narsoplimab BLA for the Treatment of HSCT-TMA
- Omeros Provides Update on Separate Payment for OMIDRIA® in the ASCs
- Omeros to Present at the Cantor Virtual Global Healthcare Conference
- Expert Panel Points to Central Role of Endothelial Injury and Lectin Pathway Activation in Critically Ill COVID-19 Patients
- Omeros’ Investigational New Drug Application for OMS906 Cleared by FDA
- Omeros Announces Pricing of Public Offerings
- Omeros Announces Proposed Public Offerings of Common Stock and Convertible Senior Notes
- Omeros Corporation Reports Second Quarter 2020 Financial Results
- Omeros Corporation Reports Recovery and Survival of All Patients in Study Evaluating Narsoplimab for Treatment of COVID-19-Associated Acute Respiratory Distress Syndrome
- Omeros’ Narsoplimab Pivotal Trial Data Shared in Oral Presentation at Annual European Hematology Association Congress
- Omeros’ Narsoplimab Pivotal Trial Data to be Shared as an Oral Presentation at Annual European Hematology Association Congress
- Omeros Corporation Announces Presentation of Narsoplimab Pivotal Trial Data at Upcoming European Hematology Association Annual Congress
- Omeros Corporation Reports First Quarter 2020 Financial Results
- Omeros Corporation to Announce First Quarter Financial Results on May 11, 2020
- Omeros Corporation Reports Fourth Quarter and Year-End 2019 Financial Results
- Omeros Corporation Reports Updated Results from Narsoplimab HSCT-TMA Clinical Trial and Highlights from Recent Clinical and CMC Meetings with FDA
- Omeros Corporation to Announce Fourth Quarter and Year-End 2019 Financial Results on March 2, 2020
- Omeros Corporation Appoints Former Amazon Treasurer Kurt Zumwalt to Board of Directors
- myTomorrows and Omeros Corporation Collaborate to Provide an Expanded Access Program for Narsoplimab
- Omeros’ Newly Presented GPR174 Immuno-oncology Data at ESMO Immuno-Oncology Congress Show Inhibition of Both Checkpoint and Tumor-Promoting Factors
- Omeros Announces Full Exercise and Closing of Underwriter’s Option to Purchase Additional Shares
- Omeros to Present GPR174 Data at the European Society for Medical Oncology 2019 Immuno-Oncology Congress in Geneva
- Omeros Announces Pricing of Upsized Public Offering of Common Stock
- Omeros Announces Proposed Public Offering of Common Stock
- Omeros Reports Positive Data Across Primary and Secondary Endpoints in Pivotal Trial of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy Patients Treated with Narsoplimab
- Product-Specific J-Code for Omeros’ OMIDRIA® is Now in Effect
- Omeros Announces Publication of Study Showing that Inhibition of MASP-2, the Key Enzyme of the Complement System’s Lectin Pathway, Protects Against Renal Injury Caused by Proteinuria
- Omeros Corporation Announces Positive Results from Phase 1 Study of its Lead PDE7 Inhibitor in Development for Addiction
- FDA Confirms Omeros’ Schedule for Rolling Review of the Company’s BLA for Narsoplimab in the Treatment of HSCT-TMA
